{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:27:49Z","timestamp":1765268869414,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Vaccination has been critical to managing the COVID-19 pandemic. Autoimmunity of the nervous system, especially among a select set of high-risk groups, can be triggered or enhanced by the contents of vaccines. Here, we report a case series of acute peripheral neuropathies following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on 11 patients (range: 30\u201390 years old) who presented at our center between January 2021 and February 2022. Methods: We obtained the patients\u2019 history and performed clinical neurological examination and electromyoneurography on all subjects. If necessary, magnetic resonance imaging and laboratory testing, including cerebrospinal fluid analysis and specific antibody testing, were performed. Results: Patients presented with peripheral neuropathies of acute onset between 1 and 40 days after vaccination with different types of COVID-19 vaccines. Most cases (9\/11) resolved with a rapid, complete or partial recovery. Conclusions: We found acute peripheral neuropathies in a set of individuals after they received vaccines against SARS-CoV-2. Albeit our observation shows that during extensive vaccination programs, negative side effects on the peripheral nervous system might occur, most of them showed benign clinical evolution. Thus, potential side effects should not hinder the prescription of vaccines. More extensive studies are needed to elucidate populations at risk of developing peripheral neuropathies and mechanisms of autoimmune response in the nervous system.<\/jats:p>","DOI":"10.3390\/medicina59030501","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T02:56:50Z","timestamp":1677812210000},"page":"501","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Series of Acute Peripheral Neuropathies in Individuals Who Received COVID-19 Vaccination"],"prefix":"10.3390","volume":"59","author":[{"given":"Egl\u0117","family":"Sukockien\u0117","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-1981","authenticated-orcid":false,"given":"Gautier","family":"Breville","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Fayolle","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-1823","authenticated-orcid":false,"given":"Umberto","family":"Nencha","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolaine","family":"Uginet","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"H\u00fcbers","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and guillain-barre syndrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10072-020-04450-1","article-title":"Italian Society of Neurology (SIN) An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID)","volume":"41","author":"Ferrarese","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Klugar, M., Riad, A., Mekhemar, M., Conrad, J., Buchbender, M., Howaldt, H.P., and Attia, S. (2021). Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology, 10.","DOI":"10.3390\/biology10080752"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41591-020-0916-2","article-title":"Real-time tracking of self-reported symptoms to predict potential COVID-19","volume":"26","author":"Menni","year":"2020","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Riad, A., Pokorn\u00e1, A., Attia, S., Klugarov\u00e1, J., Ko\u0161\u010d\u00edk, M., and Klugar, M. (2021). Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071428"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"eabj9256","DOI":"10.1126\/sciimmunol.abj9256","article-title":"COVID-19 vaccine side effects: The positives about feeling bad","volume":"6","author":"Sprent","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_8","unstructured":"Federal Office of Public Health FOPH (2023). COVID-19 Switzerland."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100236","DOI":"10.1016\/j.lanepe.2021.100236","article-title":"Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell\u2019s palsy: A population-based study","volume":"11","author":"Shibli","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"108818","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"230","author":"Arauz","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e000309","DOI":"10.1136\/bmjno-2022-000309","article-title":"Guillain-Barr\u00e9 syndrome following SARS-CoV-2 vaccination in the UK: A prospective surveillance study","volume":"4","author":"Tamborska","year":"2022","journal-title":"BMJ Neurol. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.26258","article-title":"Adenovirus COVID-19 Vaccines and Guillain-Barr\u00e9 Syndrome with Facial Paralysis","volume":"91","author":"Pegat","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_14","first-page":"e18291","article-title":"Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine","volume":"13","author":"Dalwadi","year":"2021","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinimag.2021.10.010","article-title":"Left Bell\u2019s palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report","volume":"82","author":"Cellina","year":"2022","journal-title":"Clin. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"577651","DOI":"10.1016\/j.jneuroim.2021.577651","article-title":"Genetic basis of Guillain-Barre syndrome","volume":"358","author":"Khanmohammadi","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1473-3099(21)00323-6","article-title":"Bell\u2019s palsy and SARS-CoV-2 vaccines-an unfolding story\u2014Authors\u2019 reply","volume":"21","author":"Ozonoff","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kim, S., Kang, M., Park, J.S., and Seok, H.Y. (2023). Risk and characteristics of Bell\u2019s palsy in adults as an adverse event following COVID-19 vaccination: A retrospective study. Acta Neurol. Belg., 1\u20139.","DOI":"10.1007\/s13760-023-02204-2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1212\/WNL.0000000000201376","article-title":"SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy","volume":"100","author":"Baars","year":"2023","journal-title":"Neurology"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:46:51Z","timestamp":1760122011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["medicina59030501"],"URL":"https:\/\/doi.org\/10.3390\/medicina59030501","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}